Fucidin
ApprovedSmall molecule
LEO PharmaFucidin is one of 68 small molecule programs targeting Impetigo. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Xyzal
CChattem
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Fucidin
LEO PharmaApproved
GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
Verdeso
PPadagis LLC
Phase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Dermatitis1 trial
Diabetic Foot1 trial
The Healing Effects Of Honey and Hydrogel Products On The Diabetic Foot
Completed·—·Phase 1·NCT03816618·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fucidin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company